Antiarrhythmic and antioxidant activity of novel pyrrolidin-2-one derivatives with adrenolytic properties

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 383, Issue 1, 2011, Pages 13-25

  Sapa, Jacek ^c   Nowaczyk, Alicja ^a   Kulig, Katarzyna ^b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c NONE

Author keywords

adrenoceptor blocking activity; Antiarrhythmic; Occlusion and reperfusion; Pyrrolidin 2 one derivatives

Indexed keywords

7 [2 (BENZHYDRYLOXYIMINOMETHYL)BICYCLO[2.2.1]HEPTAN 3 YL] 5 HEPTENOIC ACID; ANTIARRHYTHMIC AGENT; ANTIOXIDANT; BARIUM CHLORIDE; EP 24; EP 26; EP 28; EP 32; EP 40; EP 41; EP 43; EP 44; EP 46; EP 47; EP 67; EP 68; EP 69; EP 70; EP 71; EP 74; PHENYTOIN; QUINIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CORONARY ARTERY LIGATION; CORONARY REPERFUSION; DRUG ACTIVITY; HEART ARRHYTHMIA; MALE; NONHUMAN; QRS COMPLEX; QT PROLONGATION; RAT; TACHYCARDIA;

ADRENERGIC ANTAGONISTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIOXIDANTS; ARRHYTHMIAS, CARDIAC; BARIUM COMPOUNDS; BRAIN; CARDIAC COMPLEXES, PREMATURE; CHLORIDES; DRUG DESIGN; ELECTROCARDIOGRAPHY; HEART; HEART RATE; LIPID PEROXIDATION; MALE; MOLECULAR STRUCTURE; MYOCARDIAL REPERFUSION INJURY; PYRROLIDINONES; RATS; RATS, WISTAR; SOFTWARE; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 78751605402     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-010-0566-x     Document Type: Article

References (71)

1. OM Becker Y Marantz S Shacham B Inbal, et al. 2004 G protein-coupled receptors: in silico drug discovery in 3D Proc Nat Acad Sci USA 101 11304 11309 1:CAS:528:DC%2BD2cXmvVKgtL4%3D 10.1073/pnas.0401862101 15277683 (Pubitemid 39038342)
2. BG Benfey MS Elfellah RI Ogilvie DR Varma 1984 Anti-arrhythmic effects of prazosin and propranolol during coronary artery occlusion and re-perfusion in dogs and pigs Br J Pharmacol 82 717 725 1:CAS:528:DyaL2cXlt1aktbk%3D 6743921
3. M Bernauer I Ernenputsch 1988 Antagonistic effects of alpha-adrenoceptor blocking agents on arrhythmias, enzyme release, and myocardial necrosis in isolated rat hearts with coronary occlusion and reperfusion Naunyn- Schmiedeberg's Arch Pharmacol 338 88 95 1:CAS:528:DyaL1cXls1eiurk%3D 10.1007/BF00168817
4. M Bernier AS Manning DJ Hearse 1989 Ischemia-induced and reperfusion-induced arrhythmias: importance of heart rate Am J Physiol 256 H1344 H1352 1:CAS:528:DyaL1MXktFOnsbk%3D 2719133
5. M Bohm F Diet G Feiler, et al. 1988 [alpha]-Adrenoceptors and [alpha]-Adrenoceptor-Mediated Positive Inotropic Effects in Failing Human Myocardium J Cardiovasc Pharmacol 12 357 1:STN:280:DyaL1M7htFGqtA%3D%3D 10.1097/00005344-198809000-00015 2464110
6. MR Boyett SM Harrison NC Janvier SO McMorn JM Owen Z Shui 1996 A list of vertebrate cardiac ionic currents nomenclature, properties, function and cloned equivalents Cardiovasc Res 32 455 481 1:CAS:528:DyaK28XmtVSlsLk%3D 8881508
7. J Bralet JP Didier D Moreau LH Opie L Rochette 1985 Effect of alpha-adrenoceptor antagonists (phentolamine, nicergoline and prazosin) on reperfusion arrhythmias and noradrenaline release in perfused rat heart Br J Pharmac 84 009 018 1:CAS:528:DyaL2MXhvFOktLY%3D
8. OE Brodde H Bruck K Leineweber 2006 Cardiac adrenoceptors: physiological and pathophysiological relevance J Pharm Sci 100 323 337 1:CAS:528: DC%2BD28XmvVWqu7o%3D 10.1254/jphs.CRJ06001X (Pubitemid 44609527)
9. RR Brooks KE Miller JF Carpenter 1989 Broad sensitivity of rodent arrhythmia models to class I, II, III, and IV antiarrhythmic agents Proc Soc Exp Biol Med 191 201 209 1:CAS:528:DyaL1MXktlegurY%3D 2726785
10. E Carmeliet 1999 Cardiac ionic currents and acute ischemia: from channels to arrhythmias Physiol Rev 79 917 1017 1:CAS:528:DyaK1MXksFemtrg%3D 10390520
11. G Chiu S Li PJ Connolly, et al. 2008 Phenylpiperazinyl) cyclohexylureas: discovery of α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) Bioorg Med Chem 18 640 644 1:CAS:528:DC%2BD1cXosFWmtQ%3D%3D 10.1016/j.bmcl.2007.11.068
12. F Clerck H Rong Lu K Rossem A Hermans K Ammel 2002 In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity Fundam Clin Pharmacol 16 125 140 10.1046/j.1472-8206.2002.00081.x 12031065 (Pubitemid 34587797)
13. WS Colucci 1982 Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications Ann Inter Med 97 67 77 1:CAS:528:DyaL38XkvVCnu7Y%3D
14. PB Corr F Witkowski 1984 Arrhythmias associated with reperfusion: basic insights and clinical relevance J Cardiovasc Pharmacol 6 S903 6084147
15. PB Corr PB Penkoske BE Sobel 1978 Adrenergic influences on arrhythmias due to coronary occlusion and reperfusion Br Heart J 40 suppl 62 70
16. PB Corr JA Shayman JB Kramer RJ Kipnis 1981 Increased alpha-adrenergic receptors in ischemic cat myocardium: a potential mediator of electrophysiological derangements J Clin Invest 67 1232 1236 1:CAS:528:DyaL3MXhslagtLc%3D 10.1172/JCI110139 6259215
17. Corr PB, Yamada KA, Witkowski FX (1986) Mechanisms controlling cardiac autonomic function and their relation to arrhythmogenesis. In: Fozzard HA, Jennings RB, Katz AM, Morgan HE (eds) The heart and cardiovascular system, scientific foundations. Raven Press, New York, pp 1343-1403
18. W Crumb I Cavero 1999 QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development Pharm Sci Technolo Today 7 270 280 10.1016/S1461-5347(99)00172-8 (Pubitemid 29331975)
19. MJ Curtis BA Macleod JA Walker 1987 Models for the study of arrhythmias in myocardial ischaemia and infarction: the use of the rat J Moll Cell Cardiol 19 399 419 1:CAS:528:DyaL2sXksFKlu78%3D 10.1016/S0022-2828(87)80585-0 (Pubitemid 17099003)
20. D Dumez L Patmore P Ferrandon M Allely JM Armstrong 1989 Electrophysiologic, antiarrhythmic, and cardioprotective effects of N-[3, 5 dichlorophenyl] 4-[4-hydroxy-2-methoxy-phenyl] piperazine carboxamidine dihydrochloride (RS-87337) J Cardiovasc Pharmacol 14 184 193 1:CAS:528:DyaL1MXlt1KltLk%3D 10.1097/00005344-198908000-00002 2476590
21. E Elmas P Ahmad-Nejad C Weiss, et al. 2008 Plasminogen activator inhibitor-1 (PAI-1), toll-like receptor 4 (TLR4), factor II (FII), FXIII and fibrinogen polymorphisms are not associated with the prevalence of sudden death due to ventricular fibrillation during myocardial infarction Clin Chem Lab Med 46 1329 1331 1:CAS:528:DC%2BD1cXht1ektr%2FP 10.1515/CCLM.2008.265 18785870
22. JC Estrada D Darbar 2008 Clinical use of and future perspectives on antiarrhythmic drugs Eur J Clin Pharmacol 64 1139 1146 1:CAS:528: DC%2BD1cXhsVCktLrJ 10.1007/s00228-008-0555-x 18762931
23. M Fleisher S Belyakov D Jansone, et al. 2009 Investigation of the structure and prediction of the biological activity of 1, 3-bis (3-cyano-6, 6-dimethyl-2-oxo-5, 6-dihydro-2H-pyran-4-yl)-2-(4-methoxyphenyl) propane Chem Heterocycl Compd 45 531 535 1:CAS:528:DC%2BD1MXhtVygsrbL 10.1007/s10593-009- 0303-x
24. Frisch MJ, Trucks GW, Schlegel HB et al (2004) Gaussian 03, revision D.01. Gaussian, Inc., Wallingford
25. GaussView, Version 4.1, Semichem, (2003) Inc., Shawnee Mission, KS
26. K Gholivand N Oroujzadeh MF Erben, et al. 2009 Synthesis, spectroscopy, computational study and prospective biological activity of two novel 1, 3, 2-diazaphospholidine-2, 4, 5-triones Polyhedron 28 541 547 1:CAS:528: DC%2BD1MXhs1emtrs%3D 10.1016/j.poly.2008.11.024
27. Golan DE, Tashjian AH, Armstrong EJ, Armstrong AW (2008) Principles of pharmacology: the pathophysiologic basis of drug therapy. Lippincott Williams & Wilkins, London
28. JJ Goldberger ME Cain SH Hohnloser, et al. 2008 American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention J Am Coll Cardiol 52 1179 1199 10.1016/j.jacc.2008.05.003 18804749
29. ES Hayes MK Pugsley AL Goldin MJA Walker 2002 Sodium channel blocking and antiarrhythmic actions of the novel arylpiperazine RSD992 Pharmacol Res 46 19 29 1:CAS:528:DC%2BD38Xms1Wmtr0%3D 10.1016/S1043-6618(02)00077-4 12208117 (Pubitemid 35300789)
30. Z He L Huang Y Wu, et al. 2008 DDPH: improving cognitive deficits beyond its alpha 1-adrenoceptor antagonism in chronic cerebral hypoperfused rats Eur J Pharmacol 88 178 188 10.1016/j.ejphar.2008.03.060
31. G Heusch 1990 Alpha-adrenergic mechanisms in myocardial ischemia Cir 81 1 1:CAS:528:DyaK3cXhtFKmsLk%3D
32. HV Huikuri A Castellanos RJ Myerburg 2001 Sudden death due to cardiac arrhythmias N Engl J Med 345 1473 1482 1:STN:280:DC%2BD38%2FmsFGnuw%3D%3D 10.1056/NEJMra000650 11794197
33. T Ino MC Fishbein W Mandel PS Chen H Karaguezian 1995 Cellular mechanisms of ventricular bipolar electrograms showing double and fractionated potentials J Am Coll Cariol 26 1080 1089 1:STN:280:DyaK28%2FgslemtA%3D%3D 10.1016/0735-1097(95)00256-7
34. KS Jain JB Bariwal MK Kathiravan, et al. 2008 Recent advances in selective α1-adrenoreceptor antagonists as antihypertensive agents Bioorg Med Chem 16 4759 4800 1:CAS:528:DC%2BD1cXlvVSqtr0%3D 10.1016/j.bmc.2008.02.091 18378462 (Pubitemid 351625861)
35. D Kromhout 2007 Epidemiology of cardiovascular diseases in Europe Public Health Nutr 4 441 457
36. K Kulig J Sapa D Maciag B Filipek B Malawska 2007 Synthesis and pharmacological evaluation of new 1-[3-(4-arylpiperazin-1-yl)-2-hydroxypropyl]- pyrrolidin-2-one derivatives with anti-arrhythmic, hypotensive, and alpha-adrenolytic activity Arch Pharm Weinheim 340 9 466 475 1:CAS:528:DC%2BD2sXhtFWmu7nE 10.1002/ardp.200700039 17806129 (Pubitemid 47478067)
37. D Lamontagne N Yamaguchi R Nadeau J Champlan D Godin N Campeau 1986 Effects of sotalol, (-)-propranolol and prazosin on reperfusion-induced arrhythmias and increased cardiac norepinephrine release Eur J Pharmacol 123 1 10 1:CAS:528:DyaL28XktFyjtbg%3D 10.1016/0014-2999(86)90680-1 2872070 (Pubitemid 16050971)
38. JS Landzberg JD Parker DF Gauthier, et al. 1991 Effects of myocardial alpha 1-adrenergic receptor stimulation and blockade on contractility in humans Cir 84 1608 1:STN:280:DyaK38%2Fgs1Slsg%3D%3D
39. O Langendorff 1895 Untersuchungen am überlebenden Säugethierherzen Pflügers Arch 61 291 332 10.1007/BF01812150
40. WF Lubbe PS Daries 1978 Ventricular arrhythmias associated with coronary artery occlusion and reperfusion in the isolated perfused rat heart: a model for assessment of antifibrillatory action of antiarrhythmic agents Cardiovasc Res 12 212 220 1:CAS:528:DyaE1cXlsVSjtbg%3D 10.1093/cvr/12.4.212 657177
41. B Malawska K Kulig B Filipek J Sapa D Macia̧g M Zygmunt L Antkiewicz-Michaluk 2002 Synthesis, antiarrhythmic, and antihypertensive effects of novel 1-[2-hydroxy- or 1-[2-acetoxy-3-arylalkylamino)-propyl]-pyrrolidin-2- one derivatives with adrenolytic activity Eur J Med Chem 37 3 183 195 1:CAS:528:DC%2BD38XitFWnsLs%3D 10.1016/S0223-5234(01)01321-6 11900863 (Pubitemid 34251182)
42. 1-adrenoceptor antagonist Farmaco 60 793 803 1:CAS:528:DC%2BD2MXhtFersr7F 10.1016/j.farmac.2005.08.002 16181628 (Pubitemid 41483037)
43. A Marwaha RK Goel MP Mahajan 2007 PASS-predicted design, synthesis and biological evaluation of cyclic nitrones as nootropics Bioorg Med Chem 17 5251 5255 1:CAS:528:DC%2BD2sXpt1emu7Y%3D 10.1016/j.bmcl.2007.06.071 (Pubitemid 47259643)
44. P Matyus A Varro JG Papp H Wamhoff I Varga L Virag 1997 Antiarrhythmic agents: current status and perspectives Med Res Rev 17 427 451 1:CAS:528:DyaK2sXlvFaqurg%3D 10.1002/(SICI)1098-1128(199709)17:5<427::AID- MED1>3.0.CO;2-W 9276860 (Pubitemid 27376496)
45. GA Michelotti DT Price DA Schwinn 2000 alpha 1-adrenergic receptor regulation: basic science and clinical implications Pharmacol Ther 88 281 309 1:CAS:528:DC%2BD3MXjtFGnsL4%3D 10.1016/S0163-7258(00)00092-9 11337028 (Pubitemid 32406055)
46. Y Miyasaka ME Barnes BJ Gersh, et al. 2006 Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Cir 114 119 10.1161/CIRCULATIONAHA.105.595140 (Pubitemid 44420743)
47. S Nattel L Carlsson 2006 Innovative approaches to anti-arrhythmic drug therapy Nat Rev Drug Discov 5 1034 1050 1:CAS:528:DC%2BD28Xht1Kju7vJ 10.1038/nrd2112 17139288 (Pubitemid 44835130)
48. BJ Northover 1983 A comparison of the electrophysiological actions of phentolamine with those of some other antiarrhythmic drugs on tissues isolated from the rat heart Br J Pharmacol 80 85 93 1:CAS:528:DyaL3sXlvVOmsb4%3D 6140056
49. A Nowaczyk K Kulig B Malawska 2009 1-(3-(4-arylpiperazin-1-yl)-propyl)- pyrrolidin-2-one derivatives as α1-adrenoceptor antagonists: a QSAR studies QSAR Comb Sci 28 979 988 1:CAS:528:DC%2BD1MXhtFCqu7bN 10.1002/qsar.200810145
50. 1-adrenoceptor antagonists and antiarrhythmic agents Minf 29 343 351 1:CAS:528:DC%2BC3cXlt1Cjt7o%3D
51. Page C, Curtis M, Sutter M, Walker M, Hoffman B (2002) Integrated pharmacology. Mosby, Edinburgh, pp 361-376
52. PASS (Prediction of Biological Activity Spectra) 2010. Available at: http://www.ibmh.msk.su/PASS
53. Poroikov V, Filimonov D (eds) (2005) PASS: prediction of biological activity spectra for substances. Taylor & Francis Group, LLC, Boca Raton
54. V Poroikov DA Filimonov YV Borodina, et al. 2000 Robustness of biological activity spectra predicting by computer program PASS for noncongeneric sets of chemical compounds J Chem Inf Comput Sci 40 1349 1355 1:CAS:528: DC%2BD3cXmvFSrsLs%3D 11128093
55. MW Rich 2009 Epidemiology of atrial fibrillation J Interv Card Electrophysiol 25 3 8 10.1007/s10840-008-9337-8 19160031
56. A Rohilla S Rohilla G Singh, et al. 2010 Myocardial ischemic preconditioning: a novel approach to cardioprotection J Pharm Res 3 132 140 1:CAS:528:DC%2BC3cXht1WjsLnF
57. A Sharma B Lee B Saffitz B Sobel P Corr 1983 Alpha adrenergic mediated accumulation of calcium in reperfused myocardium J Clin Invest 72 802 818 1:CAS:528:DyaL3sXmtVGrsbw%3D 10.1172/JCI111051 6136527
58. DJ Sheridan PA Penkoske BE Sobel PB Corr 1980 Alpha adrenergic contributions to dysrhythmia during myocardial ischemia and reperfusion in cats J Clin Invest 65 161 171 1:CAS:528:DyaL3cXpt1amug%3D%3D 10.1172/JCI109647 6243138
59. CF Starmer AA Laastra VW Nesterenhs AO Grant 1991 Proarrhythmic response to sodium channel blockade. Theor Model Numerical Experiments Circulation 84 1364 1:CAS:528:DyaK3MXmslShu7Y%3D 1653123
60. JR Stewart WE Burmeister J Burmeister BR Lucchesi 1980 Electrophysiologic and antiarrhythmic effects of phentolamine in experimental coronary artery occlusion and reperfusion in the dog J Cardiovasc Pharmacol 2 77 91 1:CAS:528:DyaL3cXhvFWgs7s%3D 10.1097/00005344-198001000-00009 6154207
61. S Sundeep 2001 Protecting the myocardium from ischemic injury. A critical role for alpha1-adrenoreceptors? Chest 119 1242 1249 10.1378/chest.119.4.1242 (Pubitemid 32679453)
62. Szekeres L, Papp JG (1975) Handbook of experimental pharmacology, vol XVI/3. Springer Verlag, New York
63. FT Thandroyen MG Worthington L Higginson LH Opie 1983 The effect of alpha-adrenoceptor antagonist agents on reperfusion ventricular fibrillation and metabolic status in the isolated perfused rat heart J Am Coll Cardiol 1 1056 1066 1:CAS:528:DyaL3sXltlOlsbg%3D 10.1016/S0735-1097(83)80108-9 6131912
64. M Thiyagarajan 2002 alpha-adrenoceptor antagonists in the treatment of benign prostate hyperplasia Pharmacol 65 119 128 1:CAS:528:DC%2BD38XktVensLk%3D 10.1159/000058037 (Pubitemid 34621746)
65. R Tolg T Kurz M Ungerer J Schreieck B Gorge G Richard 1997 Influence of alpha- and beta-adrenoceptor antagonists on ventricular fibrillation in ischemic rat hearts Naunyn-Schmiedeberg's Arch Pharmacol 356 62 68 1:STN:280: DyaK2szntF2htA%3D%3D 10.1007/PL00005029 (Pubitemid 27276153)
66. T Uematsu S Vozeh HR Ha RP Hof F Follath 1986 Coronary ligation-reperfusion arrhythmia models in anesthetized rats and isolated perfused rat hearts concentration-effect relationships of lidocaine J Pharmacol Meth 16 53 61 1:CAS:528:DyaL28XltVOrtrY%3D 10.1016/0160-5402(86)90028-8 (Pubitemid 16068439)
67. EM Vaughan Williams 1975 Classification of antidysrhythmic drugs Pharmacol Ther B1 115 138
68. Vaughan Williams EM (1981) Pharmacology of anti-arrhythmic agents. Pergamon, Oxford, pp 125-150
69. MJA Walker MJ Curtis DJ Hearse, et al. 1988 Cardiovasc Res 22 447 455 1:STN:280:DyaL1Mzgtl2kug%3D%3D 10.1093/cvr/22.7.447 3252968
70. T Yue HY Cheng PG Lysko PJ Mckenna R Feuerstein JL Gu KA Lysko LL Davis G Feuerstein 1992 Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger J Pharmacol Exp Ther 263 1
71. H Zhong KP Minneman 1999 A1-Adrenoceptor subtypes Eur J Pharmacol 375 261 276 1:CAS:528:DyaK1MXks1Crs7c%3D 10.1016/S0014-2999(99)00222-8 10443582 (Pubitemid 29317610)